open access

Vol 72, No 1 (2021)
Review paper
Published online: 2021-02-26
Submitted: 2020-10-14
Accepted: 2020-11-19
Get Citation

Pituitary transcription factors in the immunohistochemical and molecular diagnosis of pituitary tumours — a systematic review

Iulia Florentina Burcea, Valeria-Nicoleta Năstase, Cătălina Poiană
DOI: 10.5603/EP.a2020.0090
·
Pubmed: 33749818
·
Endokrynologia Polska 2021;72(1):53-63.

open access

Vol 72, No 1 (2021)
Review Article
Published online: 2021-02-26
Submitted: 2020-10-14
Accepted: 2020-11-19

Abstract

Introduction: Although histopathology remains in the first line of the diagnosis of pituitary pathology, immunohistochemistry and molecular biology are currently in charge of providing a more accurate characterisation of tumours in this field.

Material and methods: A systematic review of the literature was performed, using the PubMed and SCOPUS databases, with terms that included transcription factors involved in the development of pituitary tumours: T-PIT, PIT-1, and SF-1.

Results: The results showed different perspectives, but the evidence is in favour of a multifold immunohistochemical analysis that must include pituitary transcription factors for a highly accurate diagnosis, prognosis, and guidance of (multimodal) therapy.

Conclusions: By using transcription factors, the understanding of the structure and function of the recently defined pituitary neuroendocrine tumours has made significant progress. This approach brings the (sub)classification of pituitary tumours, using cell types and cell lineages, with clinical and molecular implications and therapeutic results. 

Abstract

Introduction: Although histopathology remains in the first line of the diagnosis of pituitary pathology, immunohistochemistry and molecular biology are currently in charge of providing a more accurate characterisation of tumours in this field.

Material and methods: A systematic review of the literature was performed, using the PubMed and SCOPUS databases, with terms that included transcription factors involved in the development of pituitary tumours: T-PIT, PIT-1, and SF-1.

Results: The results showed different perspectives, but the evidence is in favour of a multifold immunohistochemical analysis that must include pituitary transcription factors for a highly accurate diagnosis, prognosis, and guidance of (multimodal) therapy.

Conclusions: By using transcription factors, the understanding of the structure and function of the recently defined pituitary neuroendocrine tumours has made significant progress. This approach brings the (sub)classification of pituitary tumours, using cell types and cell lineages, with clinical and molecular implications and therapeutic results. 

Get Citation

Keywords

pituitary adenoma; pituitary transcription factors; immunohistochemistry; aggressive; systematic review

About this article
Title

Pituitary transcription factors in the immunohistochemical and molecular diagnosis of pituitary tumours — a systematic review

Journal

Endokrynologia Polska

Issue

Vol 72, No 1 (2021)

Article type

Review paper

Pages

53-63

Published online

2021-02-26

DOI

10.5603/EP.a2020.0090

Pubmed

33749818

Bibliographic record

Endokrynologia Polska 2021;72(1):53-63.

Keywords

pituitary adenoma
pituitary transcription factors
immunohistochemistry
aggressive
systematic review

Authors

Iulia Florentina Burcea
Valeria-Nicoleta Năstase
Cătălina Poiană

References (82)
  1. Dworakowska D, Grossman AB. The pathophysiology of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. 2009; 23(5): 525–541.
  2. Melmed S. Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 2011; 7(5): 257–266.
  3. Mertens F, Gremeaux L, Chen J, et al. Pituitary tumors contain a side population with tumor stem cell-associated characteristics. Endocr Relat Cancer. 2015; 22(4): 481–504.
  4. Megnis K, Mandrika I, Petrovska R, et al. Functional Characteristics of Multipotent Mesenchymal Stromal Cells from Pituitary Adenomas. Stem Cells Int. 2016; 2016: 7103720.
  5. Vankelecom H, Chen J. Pituitary stem cells: where do we stand? Mol Cell Endocrinol. 2014; 385(1-2): 2–17.
  6. Lopes MB. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017; 134(4): 521–535.
  7. Asa SL, Casar-Borota O, Chanson P, et al. attendees of 14th Meeting of the International Pituitary Pathology Club, Annecy, France, November 2016. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr Relat Cancer. 2017; 24(4): C5–C8.
  8. Ho KKY, Fleseriu M, Wass J, et al. A tale of pituitary adenomas: to NET or not to NET : Pituitary Society position statement. Pituitary. 2019; 22(6): 569–573.
  9. Villa C, Vasiljevic A, Jaffrain-Rea ML, et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch. 2019; 475(6): 687–692.
  10. Trouillas J, Jaffrain-Rea ML, Vasiljevic A, et al. How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers (Basel). 2020; 12(2).
  11. Marinescu MC, Baciu I, Baculescu N, et al. Improvement of acromegaly control with multimodal therapy in Romania. Endokrynol Pol. 2020; 71(3): 235–239.
  12. Liu J, He Y, Zhang X, et al. Clinicopathological analysis of 250 cases of pituitary adenoma under the new WHO classification. Oncol Lett. 2020; 19(3): 1890–1898.
  13. Pasternak-Pietrzak K, Moszczyńska E, Jurkiewicz E, et al. Paediatric Cushing's disease - a literature review of epidemiology, pathogenesis, clinical symptoms, and diagnostics. Endokrynol Pol. 2020; 71(1): 87–95.
  14. Torregrosa-Quesada ME, García-Martínez A, Silva-Ortega S, et al. How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria? Cancers (Basel). 2019; 11(12).
  15. Peng A, Dai H, Duan H, et al. A machine learning model to precisely immunohistochemically classify pituitary adenoma subtypes with radiomics based on preoperative magnetic resonance imaging. Eur J Radiol. 2020; 125: 108892.
  16. Mete O, Cintosun A, Pressman I, et al. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol. 2018; 31(6): 900–909.
  17. Mete O, Cintosun A, Pressman I, et al. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod Pathol. 2018; 31(6): 900–909.
  18. Sanchez-Tejada L, Sanchez-Ortiga R, Lamas C, et al. Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas. PLoS One. 2017; 12(7): e0180039.
  19. García-Martínez A, Sottile J, Fajardo C, et al. Is it time to consider the expression of specific-pituitary hormone genes when typifying pituitary tumours? PLoS One. 2018; 13(7): e0198877.
  20. Chinezu L, Vasiljevic A, Trouillas J, et al. Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. Eur J Endocrinol. 2017; 176(2): 195–201.
  21. Nishioka H, Inoshita N, Mete O, et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Pathol. 2015; 26(4): 349–355.
  22. Balogun JA, Monsalves E, Juraschka K, et al. Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics. Endocr Pathol. 2015; 26(1): 63–70.
  23. Lee JC, Pekmezci M, Lavezo JL, et al. Utility of Pit-1 Immunostaining in Distinguishing Pituitary Adenomas of Primitive Differentiation from Null Cell Adenomas. Endocr Pathol. 2017; 28(4): 287–292.
  24. Nishioka H, Inoshita N, Mete O, et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Pathol. 2015; 26(4): 349–355.
  25. Mete O, Asa SL. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocr Pathol. 2020; 31(4): 330–336.
  26. Lamolet B, Pulichino AM, Lamonerie T, et al. A Pituitary Cell-Restricted T Box Factor, Tpit, Activates POMC Transcription in Cooperation with Pitx Homeoproteins. Cell. 2001; 104(6): 849–859.
  27. Raverot G, Wierinckx A, Jouanneau E, et al. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Eur J Endocrinol. 2010; 163(1): 35–43.
  28. Tani Y, Sugiyama T, Izumiyama H, et al. Differential gene expression profiles of POMC-related enzymes, transcription factors and receptors between non-pituitary and pituitary ACTH-secreting tumors. Endocr J. 2011; 58(4): 297–303.
  29. Tabuchi Y, Kitamura T, Fukuhara A, et al. Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing's disease and subclinical Cushing's disease. Endocr J. 2016; 63(6): 545–554.
  30. Fratticci A, Grieco FA, Spilioti C, et al. Differential expression of neurogenins and NeuroD1 in human pituitary tumours. J Endocrinol. 2007; 194(3): 475–484.
  31. Tamanini JV, Dal Fabbro M, de Freitas LL, et al. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings. Neurosurg Focus. 2020; 48(6): E12.
  32. Suzuki M, Egashira N, Kajiya H, et al. ACTH and alpha-subunit are co-expressed in rare human pituitary corticotroph cell adenomas proposed to originate from ACTH-committed early pituitary progenitor cells. Endocr Pathol. 2008; 19(1): 17–26.
  33. Cooper O, Ben-Shlomo A, Bonert V, et al. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer. 2010; 1(2): 80–92.
  34. Langlois F, Lim DS, Yedinak CG, et al. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review. Pituitary. 2018; 21(1): 32–40.
  35. Turchini J, Sioson L, Clarkson A, et al. Utility of GATA-3 Expression in the Analysis of Pituitary Neuroendocrine Tumour (PitNET) Transcription Factors. Endocr Pathol. 2020; 31(2): 150–155.
  36. Araujo RV, Chang CV, Cescato VAS, et al. PROP1 overexpression in corticotrophinomas: evidence for the role of PROP1 in the maintenance of cells committed to corticotrophic differentiation. Clinics (Sao Paulo). 2013; 68(6): 887–891.
  37. Liu NA, Araki T, Cuevas-Ramos D, et al. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease. J Clin Endocrinol Metab. 2015; 100(7): 2557–2564.
  38. Neou M, Villa C, Armignacco R, et al. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell. 2020; 37(1): 123–134.e5.
  39. Asa SL, Puy LA, Lew AM, et al. Cell type-specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab. 1993; 77(5): 1275–1280.
  40. Wu J, Li X, Liu X. Pit-1 mRNA and protein expression in human pituitary adenomas. Int J Clin Exp Pathol. 2016; 9: 7060–8.
  41. Orciani M, Davis S, Appolloni G, et al. Isolation and characterization of progenitor mesenchymal cells in human pituitary tumors. Cancer Gene Ther. 2015; 22(1): 9–16.
  42. Japón MA, Urbano AG, Sáez C, et al. Glial-derived neurotropic factor and RET gene expression in normal human anterior pituitary cell types and in pituitary tumors. J Clin Endocrinol Metab. 2002; 87(4): 1879–1884.
  43. Cañibano C, Rodriguez NL, Saez C, et al. The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth. EMBO J. 2007; 26(8): 2015–2028.
  44. Lew AM, Elsholtz HP. Cloning of the human cDNA for transcription factor Pit-1. Nucleic Acids Res. 1991; 19(22): 6329.
  45. Pellegrini I, Barlier A, Gunz G, et al. Pit-1 gene expression in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab. 1994; 79(1): 189–196.
  46. Sanno N, Teramoto A, Matsuno A, et al. In situ hybridization analysis of Pit-1 mRNA and hormonal production in human pituitary adenomas. Acta Neuropathol. 1996; 91(3): 263–268.
  47. Li C, Xie W, Rosenblum JS, et al. Somatic SF3B1 hotspot mutation in prolactinomas. Nat Commun. 2020; 11(1): 2506.
  48. Kobayashi I, Oka H, Naritaka H, et al. Expression of Pit-1 and growth hormone-releasing hormone receptor mRNA in human pituitary adenomas: difference among functioning, silent, and other nonfunctioning adenomas. Endocr Pathol. 2002; 13(2): 83–98.
  49. Wang ELu, Qian ZR, Yamada S, et al. Clinicopathological characterization of TSH-producing adenomas: special reference to TSH-immunoreactive but clinically non-functioning adenomas. Endocr Pathol. 2009; 20(4): 209–220.
  50. Căpraru OM, Gaillard C, Vasiljevic A, et al. Diagnosis, pathology, and management of TSH-secreting pituitary tumors. A single-center retrospective study of 20 patients from 1981 to 2014. Ann Endocrinol (Paris). 2019; 80(4): 216–224.
  51. Teramoto A, Sanno N, Tahara S, et al. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment. Acta Neuropathol. 2004; 108(2): 147–153.
  52. Aydin S, Comunoglu N, Ahmedov ML, et al. Clinicopathologic Characteristics and Surgical Treatment of Plurihormonal Pituitary Adenomas. World Neurosurg. 2019; 130: e765–e774.
  53. Rak B, Maksymowicz M, Grzywa TM, et al. Pituitary tumours — a large retrospective single-centre study of over 2300 cases. Experience of a tertiary reference centre. Endokrynol Pol. 2020; 71(2): 116–125.
  54. Mete O, Alshaikh OM, Cintosun A, et al. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. Endocr Pathol. 2018; 29(4): 332–338.
  55. Behling F, Honegger J, Skardelly M, et al. High Expression of Somatostatin Receptors 2A, 3, and 5 in Corticotroph Pituitary Adenoma. Int J Endocrinol. 2018; 2018: 1763735.
  56. Nishioka H, Hara T, Nagata Y, et al. Inherent Tumor Characteristics That Limit Effective and Safe Resection of Giant Nonfunctioning Pituitary Adenomas. World Neurosurg. 2017; 106: 645–652.
  57. Nishioka H, Inoshita N, Mete O, et al. The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Pathol. 2015; 26(4): 349–355.
  58. Nishioka H, Inoshita N, Sano T, et al. Correlation between histological subtypes and MRI findings in clinically nonfunctioning pituitary adenomas. Endocr Pathol. 2012; 23(3): 151–156.
  59. Asa SL, Bamberger AM, Cao B, et al. The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J Clin Endocrinol Metab. 1996; 81(6): 2165–2170.
  60. Luo X, Ikeda Y, Parker KL, et al. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell. 1994; 77(4): 481–490.
  61. Drummond J, Roncaroli F, Grossman AB, et al. Clinical and Pathological Aspects of Silent Pituitary Adenomas. J Clin Endocrinol Metab. 2019; 104(7): 2473–2489.
  62. Manoranjan B, Mahendram S, Almenawer SA, et al. The identification of human pituitary adenoma-initiating cells. Acta Neuropathol Commun. 2016; 4(1): 125.
  63. Kasuki L, Raverot G. Definition and diagnosis of aggressive pituitary tumors. Rev Endocr Metab Disord. 2020; 21(2): 203–208.
  64. Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018; 178(1): G1–G24.
  65. Trouillas J, Roy P, Sturm N, et al. members of HYPOPRONOS. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013; 126(1): 123–135.
  66. Serioli S, Doglietto F, Fiorindi A, et al. Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Literature Review. Cancers (Basel). 2019; 11(12).
  67. Selman WR, Laws ER, Scheithauer BW, et al. The occurrence of dural invasion in pituitary adenomas. J Neurosurg. 1986; 64(3): 402–407.
  68. Meij BP, Lopes MBS, Ellegala DB, et al. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg. 2002; 96(2): 195–208.
  69. Lopes MB. The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol. 2017; 134(4): 521–535.
  70. Trouillas J, Jaffrain-Rea ML, Vasiljevic A, et al. Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions. Rev Endocr Metab Disord. 2020; 21(2): 243–251.
  71. Rogoziński D, Gilis-Januszewska A, Skalniak A, et al. Pituitary tumours in MEN1 syndrome - the new insight into the diagnosis and treatment. Endokrynol Pol. 2019; 70(5): 445–452.
  72. Srirangam Nadhamuni V, Korbonits M. Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms. Endocr Rev. 2020; 41(6).
  73. Bi WL, Horowitz P, Greenwald NF, et al. Landscape of Genomic Alterations in Pituitary Adenomas. Clin Cancer Res. 2017; 23(7): 1841–1851.
  74. Alahmadi H, Lee D, Wilson JR, et al. Clinical features of silent corticotroph adenomas. Acta Neurochir (Wien). 2012; 154(8): 1493–1498.
  75. Trouillas J, Delgrange E, Wierinckx A, et al. Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours. Neuroendocrinology. 2019; 109(1): 70–76.
  76. Sano T, Mader R, Asa SL, et al. "Honeycomb Golgi" in pituitary adenomas: not a marker of gonadotroph adenomas. Endocr Pathol. 2003; 14(4): 363–368.
  77. Cooper O, Ben-Shlomo A, Bonert V, et al. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer. 2010; 1(2): 80–92.
  78. Yunoue S, Arita K, Kawano H, et al. Identification of CD133+ cells in pituitary adenomas. Neuroendocrinology. 2011; 94(4): 302–312.
  79. Mete O, Gomez-Hernandez K, Kucharczyk W, et al. Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. Mod Pathol. 2016; 29(2): 131–142.
  80. Sjöstedt E, Bollerslev J, Mulder J, et al. A specific antibody to detect transcription factor T-Pit: a reliable marker of corticotroph cell differentiation and a tool to improve the classification of pituitary neuroendocrine tumours. Acta Neuropathol. 2017; 134(4): 675–677.
  81. Nishioka H, Hara T, Nagata Y, et al. Inherent Tumor Characteristics That Limit Effective and Safe Resection of Giant Nonfunctioning Pituitary Adenomas. World Neurosurg. 2017; 106: 645–652.
  82. McDonald WC, Banerji N, McDonald KN, et al. Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma. Arch Pathol Lab Med. 2017; 141(1): 104–112.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl